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OBJECTIVES This study investigates the effects of a change of beta-adrenergic blocking agent treatment
from metoprolol to carvedilol and vice versa in patients with heart failure (HF).
BACKGROUND Beta-blockers improve ventricular function and prolong survival in patients with HF. It has
recently been suggested that carvedilol has more pronounced effects on left ventricular
ejection fraction (LVEF) compared with metoprolol. It is uncertain whether a change from
one beta-blocker to the other is safe and leads to any change of left ventricular function.
METHODS Forty-four patients with HF due to ischemic (n 5 17) or idiopathic cardiomyopathy (n 5 27)
that had responded well to long-term treatment with either metoprolol (n 5 20) or carvedilol
(n 5 24) were switched to an equivalent dose of the respective other beta-blocker. Before and
six months after crossover of treatment, echocardiography, radionuclide ventriculography and
dobutamine stress echocardiography were performed.
RESULTS Six months after crossover of beta-blocker treatment, LVEF had further improved with both
carvedilol and metoprolol (carvedilol: 32 6 3% to 36 6 4%; metoprolol: 27 6 4% to 30 6
5%; both p , 0.05 vs. baseline), without interindividual differences. There were no changes
in either New York Heart Association functional class or any other hemodynamic parameters
at rest. Dobutamine stress echocardiography revealed a more pronounced increase of heart
rate after dobutamine infusion in metoprolol- compared with carvedilol-treated patients.
After dobutamine infusion, LVEF increased in the carvedilol- but not in the metoprolol-
treated group.
CONCLUSIONS When switching treatment from one beta-blocker to the other, improvement of LVEF in
patients with HF is maintained. Despite similar long-term effects on hemodynamics at rest,
beta-adrenergic responsiveness is different in both treatments. (J Am Coll Cardiol 2001;38:
939–46) © 2001 by the American College of Cardiology
Clinical trials have revealed beneficial effects of beta-
adrenergic blocking agent treatment in patients with heart
failure (HF). This benefit was achieved by the beta1-
selective compounds metoprolol (1) and bisoprolol (2) as
well as by the nonselective antagonist carvedilol (3). These
agents are recommended for the treatment of HF. Never-
theless, it is currently being discussed whether any of these
compounds is superior to the others in terms of hemody-
namics or prognosis (4).
A number of studies have compared clinical effects of
metoprolol and carvedilol in patients with HF (5–9). While
two of these studies (6,8) revealed no differences between
both agents regarding their effects on symptoms and left
ventricular ejection fraction (LVEF), Metra et al. (9)
observed more favorable effects of carvedilol compared with
metoprolol on LVEF, left ventricular (LV) stroke volume
and pulmonary artery pressure despite similar effects on
cardiovascular outcome. Although an improvement of ven-
tricular function may predict a reduction of mortality in
patients with HF (10), definite data on comparative mor-
tality effects of both agents are not expected before the
termination of the Carvedilol Or Metoprolol European
Trial (COMET).
Nevertheless, assuming that one agent was superior to the
other, the question that will arise in daily practice is whether
it is justified to substitute a well-tolerated beta-blocker with
another beta-blocker despite improvement of LV function
by the former one. Di Lenarda et al. (7) observed that, in
patients who were poor responders to metoprolol treatment
in terms of LV function, crossover of treatment to carvedilol
improved LVEF and reduced LV volumes. In contrast, this
study determines whether, in patients who have responded
well to metoprolol or carvedilol treatment, crossover to the
other beta-blocker, respectively, results in any change of
ventricular function, ventricular volumes and other hemo-
dynamic parameters. It further investigates the response of
either treatment group to dobutamine stress echocardiogra-
phy (DSE) in order to estimate the in vivo response to
beta-adrenergic stimulation.
METHODS
Patients with chronic HF were included due to ischemic or
idiopathic dilated cardiomyopathy. Patients were in New
York Heart Association (NYHA) class I, II or III and had
documented systolic dysfunction with an LVEF #35%
determined by radionuclide ventriculography (RNV). Con-
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comitant medication consisted of angiotensin-converting
enzyme inhibitors (82%), AT1 antagonists (3%), diuretics
(91%), digitalis (76%) and nitrates (21%) and was not
different between both groups. Exclusion criteria were
valvular disease, acute myocardial infarction within six
weeks or active angina. All patients gave informed consent
before entering the trial.
A flow chart of the study design is given in Figure 1.
Eighty patients were randomly assigned to receive open-
label metoprolol (n 5 42) or carvedilol (n 5 38). Initiation
doses were 12.5 mg of metoprolol and 3.125 mg of
carvedilol. Doses were doubled every two weeks (if toler-
ated) until target doses of 100 mg of metoprolol twice a day
or 25 mg of carvedilol twice a day, or the maximum
tolerated doses, were reached. If side effects developed that
could be related to beta-blockers, increments in doses were
delayed or doses were decreased. Before beginning treat-
ment (evaluation 1) and after at least 12 months of treat-
ment (evaluation 2), LVEF was determined by RNV.
Furthermore, LV end-diastolic diameter (EDD) and end-
systolic diameter (ESD) and fractional shortening were
determined by transthoracic echocardiography. New York
Heart Association functional class was assessed by medical
history and physical examination. Of the 80 patients, four
patients on metoprolol and three on carvedilol underwent
cardiac transplantation. Four patients on metoprolol and
one on carvedilol died before evaluation 2. Of the remaining
68 patients, 24 patients on carvedilol and 20 on metoprolol
Abbreviations and Acronyms
betaARK1 5 beta-adrenergic receptor kinase 1
COMET 5 Carvedilol Or Metoprolol European Trial
DSE 5 dobutamine stress echocardiography
EDD 5 end-diastolic diameter
ESD 5 end-systolic diameter
HF 5 heart failure
LV 5 left ventricle or left ventricular
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
PCR 5 polymerase chain reaction
RNV 5 radionuclide ventriculography
Vcfc 5 heart rate corrected velocity of
circumferential shortening
Figure 1. Study flow chart. DSE 5 dobutamine stress echocardiography.
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who had improved in terms of LVEF and NYHA class were
switched to the respective other beta-blocker. Inclusion
criteria for the crossover were a stable medication with a
minimum dose of 100 mg of metoprolol or 25 mg of
carvedilol. The crossover was performed within one day,
with the first dose of the new beta-blocker given in the
morning under continuous monitoring of hemodynamics in
our outpatient clinics. A dose of 25 mg of carvedilol was
regarded as equivalent to 100 mg of metoprolol. Since the
first patients that were switched from carvedilol to meto-
prolol frequently experienced hypotension or bradycardia,
treatment was modified by reducing the first doses of
metoprolol to 50 mg of metoprolol, equivalent to 25 mg of
carvedilol. After two weeks, the dose was doubled and
titrated to the respective maximum dose. Before (evaluation
2) and six months after crossover (evaluation 3), patients
underwent RNV, transthoracic echocardiography and phys-
ical examination. Eight patients who were switched from
carvedilol to metoprolol and six who were switched from
metoprolol to carvedilol underwent DSE before and six
months after crossover. The RNV, echocardiography and
DSE were assessed by physicians who were blinded to the
study medication of the patient. After the crossover of
beta-blocker treatment, five patients who received metopro-
lol after carvedilol and six patients from the other group
discontinued study medication for different reasons (see
Results section).
Echocardiography and DSE. Methods for transthoracic
echocardiography have been described previously (11–13).
All echocardiographic recordings were made by the same
investigator (M.C.) and were evaluated independently by
two principal investigators (K.L. and G.N.) from the
echocardiography laboratory. To obtain a parameter of
contractility that is not confounded by the influence of heart
rate, we calculated heart rate corrected velocity of circum-
ferential fiber shortening (Vcfc) by the formula Vcfc 5 FS 3
square root of HR/ejection time. The DSE was performed
under the same conditions as regular echocardiography
except that, after determination of baseline hemodynamics
at rest, increasing concentrations of dobutamine (10, 20, 30
and 40 mg/kg body weight/min) were administered intra-
venously. After 5 min, contractility and hemodynamic
parameters were determined.
Cytochrome P450 2D6 (CYP2D6) genotype determina-
tion. The CYP2D6 genotype was determined with an
improved polymerase chain reaction–restriction fragment
length polymorphism method suited for routine diagnostics
(14). DNA extraction from ethylenediaminetetraacetic
acid-blood, two first-round polymerase chain reactions
(PCR) covering the entire coding sequence with no cross
reactivity with the known CYP2D6 pseudogenes, four
second-round PCR reactions covering polymorphic sites on
the first-round products, and seven restriction enzyme
digestions of the second-round PCR products were per-
formed. The method allows .98% prediction of the poor
metabolizer phenotype in the Caucasian population.
Statistical analysis. Values are given as means 6 standard
error of the mean. Statistical analysis was performed by
Mann-Whitney U test or Wilcoxon rank-sum test. A p
value ,0.05 was considered significant.
RESULTS
Sixty-eight patients with chronic HF were investigated (Fig.
1). Thirty-four patients received metoprolol, and 34 patients
received carvedilol for at least one year. Baseline character-
istics of these patients are given in Table 1. There were no
differences regarding demographics, etiology of HF, NYHA
functional class and LVEF. Treatment with either beta-
blocker resulted in a decrease of heart rate, an increase of
LVEF and an improvement of NYHA functional class
(Table 1). The EDD decreased significantly only after
metoprolol but not after carvedilol treatment.
Of these patients, 24 on carvedilol and 20 on metoprolol
were switched to the respective other beta-blocker. Baseline
characteristics of both groups before the crossover of beta-
Table 1. Effect of Beta-Blockers Before Crossover of Treatment
Carvedilol
(n 5 34)
Baseline
After
Treatment
Metoprolol
(n 5 34)
Baseline
After
Treatment
Demographics
Age 57 6 2 60 6 1
Gender (M/F) 31/3 29/5
ICM/DCM 15/19 16/18
NYHA I/II/III 4/10/20 4/12/18
Hemodynamics
HR 93.7 6 3.3 67.7 6 1.6† 85.3 6 3.8 66.9 6 1.9†
LVEF 25.2 6 2.9 36.0 6 3.9* 25.2 6 3.9 33.1 6 5.1*
EDD 66.2 6 1.9 63.5 6 1.5 66.8 6 1.9 62.6 6 1.6*
FS 12.8 6 2.1 20.2 6 1.8* 17.4 6 3.9 26.9 6 4.4*
NYHA 2.7 6 0.2 1.7 6 0.1† 2.7 6 0.1 1.9 6 0.1†
*p , 0.05 vs. baseline; †p , 0.001 vs. baseline.
DCM 5 dilated idiopathic cardiomyopathy; EDD 5 left ventricular end-diastolic dimension; FS 5 fractional shortening;
HR 5 heart rate; ICM 5 ischemic cardiomyopathy; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart
Association functional class.
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blocker treatment are listed in Table 2. There were no
significant differences in demographics, etiology of HF and
NYHA functional class.
Patients received 47 6 3 mg carvedilol or 182 6 15 mg
metoprolol before and 48 6 3 mg carvedilol or 180 6 10 mg
metoprolol after crossover, respectively. The change from
metoprolol to carvedilol treatment was tolerated well. Nev-
ertheless, six patients discontinued carvedilol treatment and
wished to be put back on metoprolol, although none of
these patients experienced hypotension, bradycardia or
worsening of symptoms. Patients discontinued due to in-
convenient tablet size or due to the referral of their general
physician, respectively. Despite lower initial dose of meto-
prolol (50 mg metoprolol equivalent to every 25 mg of
carvedilol), five patients who were switched from carvedilol
to metoprolol did not tolerate metoprolol treatment due to
hypotension or bradycardia. Cytochrome P4502D6
(CYP2D6) is responsible for the metabolism of metoprolol.
Mutations of CYP2D6 may lead to inactivation of this
enzyme with subsequently higher plasma levels of metopro-
lol (15). Thus, the five patients who did not tolerate
metoprolol were genotyped for CYP2D6 polymorphism
and were put back on carvedilol. Of these five patients, three
patients had two functional alleles (extensive metabolizer);
one patient had one functional and one nonfunctional allele
(heterozygous individual), and one patient had two non-
functional alleles (poor metabolizer).
Six months after switching from one compound to the
other, LVEF had continuously improved in patients who
were switched from carvedilol to metoprolol as well as in
patients who were switched from metoprolol to carvedilol
(Table 2). The relative increase in LVEF was similar in both
groups. The EDD and ESD remained constant after
crossover. Additionally, heart rate, systolic and diastolic
blood pressure and NYHA functional class did not change
in either group.
Table 3 and Figure 2 display the results from DSE. The
results are given for all patients either during carvedilol or
during metoprolol treatment. In metoprolol-treated pa-
tients, maximum values (Table 3) as well as the relative
increase of heart rate (Fig. 2A) and Vcfc after maximum
dobutamine dose were higher than they were in carvedilol-
treated patients. The LV EDD (Fig. 2B) and ESD de-
creased in metoprolol-treated but not in carvedilol-treated
patients. The relative increase of LVEF was not signifi-
cantly different between both treatments (Fig. 2C). Stroke
volume increased in carvedilol-treated patients and de-
creased in metoprolol-treated patients (Fig. 2D). Cardiac
output was similar in both treatment groups (Fig. 2E).
Interestingly, systolic and median blood pressure increased
in carvedilol-treated patients but remained unchanged in
metoprolol-treated patients.
DISCUSSION
The most important findings of this study are that six
months after crossover of beta-blocker treatment, further
improvement of ventricular function occurred irrespective of
the beta-blocker used. No substantial differences in baseline
hemodynamics were observed between carvedilol- or
metoprolol-treated patients. Dobutamine stress echocardi-
ography revealed different hemodynamic responses to beta-
adrenergic stimulation in patients treated with carvedilol or
metoprolol.
LV function. Carvedilol and metoprolol improved LVEF
six months after crossover. In a recent study, carvedilol
improved LVEF in patients with idiopathic dilated cardio-
myopathy who were poor responders to metoprolol treat-
ment (7). In contrast with that trial, this investigation was
Table 2. Prospective Crossover Comparison
Carvedilol
(n 5 24)
Crossover to
Metoprolol
Metoprolol
(n 5 20)
Crossover to
Carvedilol
Demographics
Age 55 6 2 60 6 1
Gender (M/F) 20/4 17/3
ICM/DCM 7/17 10/10
NYHA I/II/III 3/15/6 4/10/6
Hemodynamics
LVEF 32.4 6 2.9 36.2 6 3.9* 27.0 6 3.9 30.3 6 5.0*
HR 69.7 6 1.7 66.6 6 2.5 69.4 6 2.9 72.1 6 3.7
BPsys 128 6 4 124 6 4 123 6 6 115 6 5
BPmed 92 6 2 89 6 3 91 6 3 85 6 3
BPdiast 74 6 2 72 6 3 75 6 2 69 6 3
EDD 67.8 6 2.3 68.1 6 2.2 65.1 6 2.6 65.7 6 2.3
ESD 53.3 6 3.2 52.6 6 3.1 56.0 6 4.4 54.2 6 5.3
FS 21.0 6 1.8 23.4 6 1.9 18.8 6 2.6 20.5 6 4.0
NYHA 2.0 6 0.3 2.0 6 0.4 2.1 6 0.2 2.0 6 0.2
*p , 0.05 vs. treatment before crossover.
BPsys (med, diast) 5 systolic (median, diastolic) blood pressure; DCM 5 dilated idiopathic cardiomyopathy; EDD 5 left
ventricular end-diastolic dimension; ESD 5 left ventricular end-systolic dimension; FS 5 fractional shortening; HR 5 heart
rate; ICM 5 ischemic cardiomyopathy; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association
functional class.
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performed in patients who had responded well to beta-
blocker treatment in terms of LVEF and NYHA functional
class. Both agents improved LVEF to a similar extent. This
is in concert with the studies of Kukin et al. (8) and
Sanderson et al. (6) who observed no differences between
metoprolol- and carvedilol-treated patients regarding
LVEF. Other trials revealed slightly (5) and significantly (9)
more pronounced improvements of hemodynamics by
carvedilol compared with metoprolol treatment. These
studies could influence the clinical decision to switch treat-
ment of patients from one beta-blocker to the other.
However, in patients already treated with beta-blockers, this
conclusion cannot be drawn since patients included in these
comparative studies were naive to beta-blockers before
initiating this treatment. Therefore, this study more closely
reflects the situation of a sudden switching of therapy. In
this investigation patients had already received beta-
blockers for more than one year, and, thus, changes in
hemodynamics may be smaller than during the first 12
months of treatment. Nevertheless, the data of the study
indicate that the time course of improvement of LV
function by beta-blockade exceeds 12 months of therapy,
irrespective of the beta-blocker used.
In contrast with former studies with metoprolol (16) and
carvedilol (17), no further reduction of LV EDD and ESD
was observed. The former studies observed a reversal of LV
remodeling during the first six (16) and 12 (17) months of
beta-blocker treatment. In the study of Doughty et al. (17),
carvedilol reduced the LV end-diastolic volume index dur-
ing the first six months of treatment, whereas, from six to 12
months of treatment, this parameter remained rather un-
changed. Thus, it may well be that LV volume reduction
decreases in the course of time, and, thus, changes of LV
volumes in this study were too small to be detected. The fact
that LVEF improved despite minor changes of LV volumes
may be due to an improvement of intrinsic contractility of
the myocardium. Since carvedilol and metoprolol improved
resting ventricular function to a similar extent, the inhibi-
tion of norepinephrine-induced maladaptive responses of
the myocardium (i.e., apoptosis [18]), rather than changes
of beta-adrenergic signal transduction (5), may be respon-
sible for the increase in resting LVEF.
Beta-adrenergic responsiveness. Dobutamine stress echo-
cardiography was used to compare the hemodynamic re-
sponse to beta-adrenergic stimulation in patients treated
with either carvedilol or metoprolol. Dobutamine is an
alpha- and beta-adrenoceptor agonist that predominantly
activates beta1-, and to a lesser extent alpha1- and beta2-
adrenoceptors. The different effects of dobutamine on he-
modynamics in carvedilol- and metoprolol-treated patients
are likely due to the different pharmacological profile of
both beta-blockers. Metoprolol is a beta1-selective (19–21)
strong inverse agonist (20,21) that upregulates ventricular
beta-adrenoceptor density (5,21), restores postreceptor
events (11) and increases cardiac norepinephrine release in
patients with HF (5). In contrast, carvedilol is a nonselective
weak inverse agonist (19–21) that does not upregulate
beta-adrenoceptors (5). Furthermore, carvedilol has alpha-
blocking (19) and antioxidant properties (22) and reduces
cardiac norepinephrine release (5).
The results from DSE indicate that, in carvedilol- and
metoprolol-treated patients, a similar increase of cardiac
output in response to beta-adrenergic stimulation is
achieved by different mechanisms. In metoprolol-treated
patients, the dobutamine-induced increase of cardiac output
was maintained by a substantial rise in heart rate. In
contrast, in carvedilol-treated patients, an increase of stroke
volume appeared to be the relevant mechanism. In a study
by Heilbrunn et al. (23) on patients with HF, improvement
of contractility in response to dobutamine after metoprolol
treatment was related to upregulation of ventricular beta-
adrenoceptor density.
Table 3. Dobutamine Stress Echocardiography
Carvedilol
Baseline
Maximum
(n 5 14) Delta %
Metoprolol
Baseline
Maximum
(n 5 14) Delta %
HR (min21) 71.5 6 2.3 85.5 6 5.1* 23.0 6 9.1 71.8 6 2.4 106.7 6 6.2‡ 48.6 6 7.1§
EF (%) 35.4 6 3.4 42.1 6 3.4‡ 22.1 6 5.3 38.7 6 3.5 43.4 6 4.1 16.4 6 8.3
EDV (ml) 219 6 17 203 6 14 24.5 6 4.9 220 6 16 181 6 18* 211.9 6 6.3
EDD (mm) 70.0 6 2.3 71.2 6 2.1 1.7 6 1.5 72.4 6 2.8 68.3 6 3.2† 25.6 6 1.7§
ESD (mm) 57.0 6 2.7 55.0 6 2.7 23.5 6 2.4 58.3 6 3.3 50.9 6 4.0‡ 212.7 6 3.4§
SV (ml) 73.1 6 6.3 82.4 6 6.8 16.2 6 7.8 80.3 6 6.4 73.0 6 7.5 23.0 6 12.8
IR (mm Hg/ml) 1.36 6 0.11 1.39 6 0.10 6.2 6 7.6 1.18 6 0.09 1.34 6 0.12 17.9 6 10.8
FS (%) 18.9 6 2.0 23.0 6 2.4* 26.7 6 10.0 20.3 6 2.3 27.7 6 3.0† 51.7 6 19.6
PDR (mm Hg/mm) 2.4 6 0.2 3.1 6 0.3‡ 29.7 6 4.1 2.3 6 0.2 3.0 6 0.4† 26.7 6 6.1
Vcfc 5 %pmin
21/ms 0.57 6 0.07 0.92 6 0.12† 61.9 6 15.2 0.63 6 0.08 1.39 6 0.25† 118.7 6 32.2§
BPsys (mm Hg) 131 6 4 163 6 7‡ 15.6 6 4.3 128 6 6 132 6 6 3.0 6 3.7§
BPmed (mm Hg) 91 6 3 106 6 5† 10.2 6 3.5 89 6 4 91 6 5 1.7 6 3.3
BPdiast (mm Hg) 71 6 3 77 6 5 4.9 6 4.6 70 6 3 70 6 5 0.6 6 4.7
C.O. (l/min) 5.2 6 0.5 6.8 6 0.5* 41.5 6 14.3 5.7 6 0.4 7.7 6 0.6* 42.5 6 15.7
*p , 0.05 vs. baseline; †p , 0.01 vs. baseline; ‡p , 0.001 vs. baseline; §p , 0.05 vs. carvedilol.
BPsys (med, diast) 5 systolic (median, diastolic) blood pressure; C.O. 5 cardiac output; EDD 5 left ventricular end-diastolic dimension; EDV 5 left ventricular end-diastolic
volume; EF 5 left ventricular ejection fraction; ESD 5 left ventricular end-systolic dimension; FS 5 fractional shortening; HR 5 heart rate; IR 5 instantaneous resistance;
PDR 5 pressure-dimension ratio; SV 5 stroke volume; Vcfc 5 heart rate corrected velocity of circumferential fiber shortening.
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In HF, ventricular protein expression and activity of
beta-adrenergic receptor kinase 1 (betaARK1) is elevated
compared with healthy controls (24). This enzyme is re-
sponsible for beta-adrenoceptor desensitization and down-
regulation, and its expression and activity have a strong
impact on cardiac contractility at baseline and after beta-
adrenergic stimulation (25). In vivo experiments on mice
revealed downregulation of betaARK1 protein levels and
activity by carvedilol, indicating that, despite a lack of
receptor upregulation, at least receptor resensitization by
carvedilol might contribute to increased cardiac contractility
in patients with HF (26). However, the fact that, in
carvedilol-treated patients, a similar increase of cardiac
output is achieved with a lower increase of heart rate but a
more pronounced increase of stroke volume may resemble a
novel and possibly more economical mechanism of beta-
adrenergic response compared with an increase of heart rate
in metoprolol-treated patients.
Since, at the time of examination, both beta-blockers
were applied at maximum achievable doses, the response to
40 mg/kg per min of dobutamine may not reflect full
beta-adrenergic stimulation. Maximum heart rates of 86 6
5 beats/min (carvedilol) and 107 6 6 beats/min (metopro-
lol) merely reflect submaximal beta-adrenoceptor occupa-
tion due to competition with the beta-blockers. Neverthe-
less, clear-cut differences in response to dobutamine were
detected even at this submaximal level of beta-adrenergic
stimulation.
In the majority of clinical trials in patients with HF, both
metoprolol and carvedilol treatment improved submaximal
exercise tolerance (27). The present data indicate that, at a
submaximal level of beta-adrenergic stimulation, the in-
crease of cardiac output is comparable in metoprolol- and
carvedilol-treated patients. Under submaximal exercise con-
ditions, similar increases of cardiac output may resemble
comparable oxygen supply of peripheral organs and muscles
and, thus, similar tolerance to exercise. In contrast with
submaximal exercise, maximal exercise tolerance is im-
Figure 2. Effects of maximum dose of dobutamine (40 mg/kg per min) on heart rate (HR) (A), end-diastolic diameter (EDD) (B), left ventricular ejection
fraction (LVEF) (C), stroke volume (SV) (D) and cardiac output (C.O.) (E). Values are given as the relative increase or decrease from baseline values,
respectively.
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proved only by metoprolol but not by carvedilol, according
to presently available data (27). This may be due to
upregulation of beta-adrenergic receptors in metoprolol-
treated patients, since an elevation of beta-adrenoceptor
density is associated with higher maximum heart rate and
oxygen consumption (28). However, such conclusions have
to be drawn carefully, since beta-adrenergic stimulation
with dobutamine is not a surrogate parameter for exercise
performance. Nevertheless, the present data may help the
understanding of different effects of both beta-blockers on
exercise tolerance in patients with HF.
Tolerability. In this study, five patients (21%) who were
switched from carvedilol to metoprolol experienced acute
hypotension or bradycardia at first dose, while none of the
patients switching from metoprolol to carvedilol had these
adverse effects. These differences were not due to unequal
beta-blockade, since after long-term treatment, patients on
metoprolol and carvedilol had the same reduction in heart
rate, and both agents were uptitrated to the target doses
recommended in large multicenter trials (1,3). In one out of
five cases, CYP2D6 poor metabolizer status could account
for bradycardia or hypotension. But granted the normal
(n 5 3) or heterozygous (n 5 1) state in the other four cases,
CYP2D6 genetic polymorphism cannot be the only reason
for metoprolol intolerance.
In human failing myocardium, metoprolol exerts more
pronounced negative inotropic effects than carvedilol (20).
This is probably related to greater inverse agonist activity of
metoprolol compared with carvedilol. Inverse agonism of a
beta-blocker is its ability to reduce the spontaneous activity
of the beta-adrenoceptor. The more intrinsic activity of
beta-adrenoceptors is reduced, the lower is cellular cyclic
adenosine monophosphate production and, thus, cardiac
inotropy and chronotropy. Thus, different inverse agonist
activity of carvedilol and metoprolol may be responsible for
the different tolerability of these agents. It is suggested that,
when initiating beta-blocker treatment in patients with HF,
carvedilol may be well tolerated since, after single dose
application, this compound maintains cardiac output (29).
Less pronounced negative inotropic effects, but also a
decrease in pulmonary wedge pressure by carvedilol due to
vasodilation may contribute to this favorable hemodynamic
effect (29). In contrast, metoprolol reduces cardiac index
after a single dose application in patients with HF (30).
Moreover, even during long-term treatment of HF patients,
cardiac index is decreased at every subsequent dose (31).
Thus, when switching the beta-blocker from carvedilol to
metoprolol, the initial metoprolol dose should not exceed
50 mg per 25 mg of carvedilol with consecutive uptitration
to the maximum tolerated dose, while a change from
metoprolol to carvedilol is well tolerated with 25 mg
carvedilol per 100 mg of metoprolol. However, these im-
mediate effects on tolerance may not justify the formulation
of conclusions about long-term tolerability.
Conclusions. Despite different pharmacological profiles of
carvedilol and metoprolol, after switching from one com-
pound to the other, both beta-blockers further improve
baseline LV function. This effect is not different between
both beta-blockers. Thus, circumstantial evidence for dif-
ferences in surrogate parameters obtained in studies com-
paring beta-blockers in patients previously naive to this
treatment does not justify switching patients from one
compound to the other. Nevertheless, the differences ob-
tained in contractile response to dobutamine provide evi-
dence for a functional significance of the differential effects
on beta-adrenergic signaling and might explain different
effects on submaximal and maximal exercise tolerance. Final
comparative conclusions on the long-term effects will not be
available before termination of the COMET trial.
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